This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huisman, C. Articles by Postmus, P. E. Search for Related Content PubMed PubMed Citation Articles by Huisman, C. Articles by Postmus, P. E. Social Bookmarking                            What's this?

Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review

From the Departments of Pulmonary Diseases and Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, the Netherlands.

Address reprint requests to P.E. Postmus, MD, PhD, Department of Pulmonary Diseases, University Hospital Vrije Universiteit, PO Box 7057, 1007 MB Amsterdam, the Netherlands; email pe.postmus{at}azvu.nl

PURPOSE: Since the increased use of first-line chemotherapy for non–small-cell lung cancer (NSCLC), second-line chemotherapy may nowadays be considered for a growing group of patients. Guidelines for second-line treatment have to be developed yet.

METHODS: We reviewed the published literature on second-line chemotherapy for NSCLC with emphasis on the role of factors such as pretreatment, response to first-line treatment, and length of disease-free-interval.

RESULTS: Thirty-four single-agent-studies and 24 multidrug-studies on second-line treatment were identified. Docetaxel has been studied most extensively and is the only agent that has been studied in randomized phase III trials. Different definitions of sensitivity applied by different authors and conflicting results have been reported about the influence of response to prior chemotherapy.

CONCLUSION: Since most patients are treated with a platinum-based regimen in the first line, platinum resistance usually is a major consideration for the use of second-line agents. We argue, however, that a more general definition of drug resistance is more appropriate than resistance to platinum only. Criteria to select NSCLC patients for second-line treatment have not been defined yet. This is also important in light of the upcoming necessity to test new drugs in pretreated instead of treated patients. Guidelines for second-line treatment of NSCLC based on clinical information on drug sensitivity to first-line therapy need to be developed.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Motohashi, K. Nagato, N. Kunii, H. Yamamoto, K. Yamasaki, K. Okita, H. Hanaoka, N. Shimizu, M. Suzuki, I. Yoshino, et al. A Phase I-II Study of {alpha}-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer J. Immunol., February 15, 2009; 182(4): 2492 - 2501. [Abstract] [Full Text] [PDF]

				F. Grossi, M. Aita, A. Follador, C. Defferrari, A. Brianti, G. Sinaccio, and O. Belvedere Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature Oncologist, April 1, 2007; 12(4): 451 - 464. [Abstract] [Full Text] [PDF]

				F. Ohyanagi, F. Taguchi, T. Horai, K. Kasahara, Y. Takeda, K. Shibata, H. Shirosaki, and M. Nishio Phase II Study of Combination Chemotherapy with Gemcitabine and Irinotecan in Patients with Advanced Non-Small-Cell Lung Cancer Previously Treated with Platinum-Containing Chemotherapy Regimens Jpn. J. Clin. Oncol., September 1, 2006; 36(9): 547 - 551. [Abstract] [Full Text] [PDF]

				K.-H. Cho, Y.-B. Song, I.-S. Choi, E.-H. Cho, J.-W. Choi, Y. M. Ahn, Y. H. Roh, S.-H. Nam, and B.-S. Kim A Phase II Study of Single-Agent Gemcitabine as a Second-Line Treatment in Advanced Non-Small Cell Lung Cancer Jpn. J. Clin. Oncol., January 1, 2006; 36(1): 50 - 54. [Abstract] [Full Text] [PDF]

				C.-L. Lai, C.-M. Tsai, C.-H. Chiu, G.-S. Wang, W.-J. Su, Y.-M. Chen, and R.-P. Perng Phase II Randomized Trial of Tri-weekly Versus Days 1 and 8 Weekly Docetaxel as a Second-line Treatment of Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 700 - 706. [Abstract] [Full Text] [PDF]

				G. Giaccone Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3235 - 3242. [Abstract] [Full Text] [PDF]

				V. Westeel, E. Quoix, D. Moro-Sibilot, M. Mercier, J.-L. Breton, D. Debieuvre, P. Richard, M.-A. Haller, B. Milleron, D. Herman, et al. Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, April 6, 2005; 97(7): 499 - 506. [Abstract] [Full Text] [PDF]

				C. Camps, E. Felip, J. M. Sanchez, B. Massuti, A. Artal, L. Paz-Ares, A. Carrato, V. Alberola, A. Blasco, J. Baselga, et al. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer Ann. Onc., April 1, 2005; 16(4): 597 - 601. [Abstract] [Full Text] [PDF]

				R. Gervais, A. Ducolone, J.-L. Breton, D. Braun, B. Lebeau, F. Vaylet, D. Debieuvre, J.-L. Pujol, J. Tredaniel, P. Clouet, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) Ann. Onc., January 1, 2005; 16(1): 90 - 96. [Abstract] [Full Text] [PDF]

				V. Gregorc, G. L. Ceresoli, I. Floriani, A. Spreafico, K. B. Bencardino, V. Ludovini, L. Pistola, Z. Mihaylova, F. R. Tofanetti, M. Ferraldeschi, et al. Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., September 15, 2004; 10(18): 6006 - 6012. [Abstract] [Full Text] [PDF]

				C. Monnerat, T. Le Chevalier, K. Kelly, C. K. Obasaju, J. Brahmer, S. Novello, T. Nakamura, A. M. Liepa, L. Bozec, P. A. Bunn Jr, et al. Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5439 - 5446. [Abstract] [Full Text] [PDF]

				F. R. Khuri, B. S. Glisson, E. S. Kim, P. Statkevich, P. F. Thall, M. L. Meyers, R. S. Herbst, R. F. Munden, C. Tendler, Y. Zhu, et al. Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors Clin. Cancer Res., May 1, 2004; 10(9): 2968 - 2976. [Abstract] [Full Text] [PDF]

				A. Spira and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392. [Full Text] [PDF]

				E. Quoix, B. Lebeau, A. Depierre, A. Ducolone, D. Moro-Sibilot, B. Milleron, J. L. Breton, E. Lemarie, J. L. Pujol, J. M. Brechot, et al. Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer Ann. Onc., January 1, 2004; 15(1): 38 - 44. [Abstract] [Full Text] [PDF]

				J.-Y. Han, D. H. Lee, H. Y. Kim, E.-A Kim, J. J. Lee, S. Y. Ju, E. H. Shin, and J. S. Lee A Phase II Study of Weekly Irinotecan and Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5909 - 5914. [Abstract] [Full Text] [PDF]

				S.-Y. Song, W. S. Kim, K. Kim, C. W. Jung, Y. H. Im, H. J. Kim, W. K. Kang, H. G. Lee, O J. Kwon, C. H. Rhee, et al. Vinorelbine, Ifosfamide, and Cisplatin Combination as Salvage Chemotherapy in Advanced Non-Small Cell Lung Cancer Jpn. J. Clin. Oncol., October 1, 2003; 33(10): 509 - 513. [Abstract] [Full Text] [PDF]

				D. H. Johnson and C. L. Arteaga Gefitinib in Recurrent Non-Small-Cell Lung Cancer: An IDEAL Trial? J. Clin. Oncol., June 15, 2003; 21(12): 2227 - 2229. [Full Text] [PDF]

				M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J.-Y. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, et al. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., June 15, 2003; 21(12): 2237 - 2246. [Abstract] [Full Text] [PDF]

				E. F. Smit, K. Mattson, J. von Pawel, C. Manegold, S. Clarke, and P. E. Postmus ALIMTA(R) (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study Ann. Onc., March 1, 2003; 14(3): 455 - 460. [Abstract] [Full Text] [PDF]

				M. A. Socinski, D. E. Morris, G. A. Masters, and R. Lilenbaum Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer Chest, January 1, 2003; 123 (2009): 226S - 243S. [Abstract] [Full Text] [PDF]

				O. Juan, A. Albert, F. Ordono, R. Casany, V. Caranana, J. M. Campos, and V. Alberola Low-dose Weekly Paclitaxel as Second-line Treatment for Advanced Non-small Cell Lung Cancer: a Phase II Study Jpn. J. Clin. Oncol., November 1, 2002; 32(11): 449 - 454. [Abstract] [Full Text] [PDF]